

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20555> holds various files of this Leiden University dissertation.

Author: Putten, Maaïke van

Title: The influence of low dystrophin levels on disease pathology in mouse models for Duchenne Muscular Dystrophy

Issue Date: 2013-02-26

References

- 't Hoen PA**, van der Wees CG, Aartsma-Rus A, Turk R, Goyenvalle A, Danos O, Garcia L, van Ommen GJ, den Dunnen JT, van Deutekom JC (2006) Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. *Pharmacogenomics* 7:281-297
- 't Hoen PA**, de Meijer EJ, Boer JM, Vossen RH, Turk R, Maatman RG, Davies KE, van Ommen GJ, van Deutekom C, den Dunnen JT (2008) Generation and characterization of transgenic mice with the full-length human DMD gene. *J Biol Chem* 283:5899-5907
- Aartsma-Rus A** (2010) Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. *RNA Biol* 7:453-461
- Aartsma-Rus A**, den Dunnen JT, van Ommen GJ (2010) New insights in gene-derived therapy: the example of Duchenne muscular dystrophy. *Ann N Y Acad Sci* 1214:199-212
- Aartsma-Rus A**, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom JC, van Ommen GJ, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. *Hum Mutat* 30:293-299
- Aartsma-Rus A**, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. *Hum Mol Genet* 12:907-914
- Aartsma-Rus A**, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC (2004a) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. *Am J Hum Genet* 74:83-92
- Aartsma-Rus A**, Janson AA, van Ommen GJ, van Deutekom JC (2007) Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. *BMC Med Genet* 8:43
- Aartsma-Rus A**, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC (2004b) Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. *Gene Ther* 11:1391-1398
- Aartsma-Rus A**, van Deutekom JC, Fokkema IF, van Ommen GJ, den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. *Muscle Nerve* 34:135-144
- Aartsma-Rus A**, van Ommen GJ (2010) Progress in therapeutic antisense applications for neuromuscular disorders. *Eur J Hum Genet* 18:146-153
- Allen DG**, Gervasio OL, Yeung EW, Whitehead NP (2010) Calcium and the damage pathways in muscular dystrophy. *Can J Physiol Pharmacol* 88:83-91
- Alter J**, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. *Nat Med* 12:175-177
- Amantana A**, Iversen PL (2005) Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. *Curr Opin Pharmacol* 5:550-555
- Angelini C** (2007) The role of corticosteroids in muscular dystrophy: a critical appraisal. *Muscle Nerve* 36:424-435
- Aoki Y**, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient *mdx* mouse. *Mol Ther* 18:1995-2005
- Apel ED**, Roberds SL, Campbell KP, Merlie JP (1995) Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. *Neuron* 15:115-126
- Araki E**, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I, Kobayashi T, Katsuki M (1997) Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. *Biochem Biophys Res Commun* 238:492-497
- Archer JD**, Vargas CC, Anderson JE (2006) Persistent and improved functional gain in *mdx* dystrophic mice after treatment with L-arginine and deflazacort. *FASEB J* 20:738-740

- Au CG**, Butler TL, Sherwood MC, Egan JR, North KN, Winlaw DS (2011) Increased connective tissue growth factor associated with cardiac fibrosis in the *mdx* mouse model of dystrophic cardiomyopathy. *Int J Exp Pathol* 92:57-65
- Azofeifa J**, Voit T, Hubner C, Cremer M (1995) X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. *Hum Genet* 96:167-176
- Baar K**, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO (2002) Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. *FASEB J* 16:1879-1886
- Baban D**, Davies KE (2008) Microarray analysis of *mdx* mice expressing high levels of utrophin: therapeutic implications for dystrophin deficiency. *Neuromuscul Disord* 18:239-247
- Beastrom N**, Lu H, Macke A, Canan BD, Johnson EK, Penton CM, Kaspar BK, Rodino-Klapac LR, Zhou L, Janssen PM, Montanaro F (2011) *mdx*^(c) mice manifest more severe muscle dysfunction and diaphragm force deficits than do *mdx* mice. *Am J Pathol* 179:2464-2474
- Beggs AH**, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM (1991) Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. *Am J Hum Genet* 49:54-67
- Bia BL**, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE, Radda GK, Clarke K (1999) Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. *J Mol Cell Cardiol* 31:1857-1862
- Billard C**, Gillet P, Signoret JL, Uicaud E, Bertrand P, Fardeau M, Barthez-Carpentier MA, Santini JJ (1992) Cognitive functions in Duchenne muscular dystrophy: a reappraisal and comparison with spinal muscular atrophy. *Neuromuscul Disord* 2:371-378
- Bjerglund NL**, Nielsen IM (1984) Turner's syndrome and Duchenne muscular dystrophy in a girl with an X; autosome translocation. *Ann Genet* 27:173-177
- Blake DJ**, Weir A, Newey SE, Davies KE (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol Rev* 82:291-329
- Bobet J**, Mooney RF, Gordon T (1998) Force and stiffness of old dystrophic *mdx* mouse skeletal muscles. *Muscle Nerve* 21:536-539
- Borrelli O**, Salvia G, Mancini V, Santoro L, Tagliente F, Romeo EF, Cucchiara S (2005) Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. *Am J Gastroenterol* 100:695-702
- Bostick B**, Yue Y, Duan D (2010) Gender influences cardiac function in the *mdx* model of Duchenne cardiomyopathy. *Muscle Nerve* 42:600-603
- Bostick B**, Yue Y, Long C, Duan D (2008) Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. *Circ Res* 102:121-130
- Bostick B**, Yue Y, Long C, Marschalk N, Fine DM, Chen J, and Duan D (2009). Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged *mdx* mice. *Mol. Ther* 17:253-261
- Bothwell JH**, Griffin JL (2011) An introduction to biological nuclear magnetic resonance spectroscopy. *Biol Rev Camb Philos Soc* 86:493-510
- Bowles DE**, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE, Grieger JC, Govindasamy L, Agbandje-McKenna M, Xiao X, Samulski RJ (2011) Phase I Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector. *Mol Ther* 20:443-455
- Boyd Y**, Buckle V, Holt S, Munro E, Hunter D, Craig I (1986) Muscular dystrophy in girls with X;autosome translocations. *J Med Genet* 23:484-490
- Brockdorff N**, Ashworth A, Kay GF, Cooper P, Smith S, McCabe VM, Norris DP, Penny GD, Patel D, Rastan S (1991) Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. *Nature* 351:329-331
- Brunelli S**, Sciorati C, D'Antona G, Innocenzi A, Covaello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E (2007) Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. *Proc Natl Acad Sci USA* 104:264-269
- Brussee V**, Tardif F, Tremblay JP (1997) Muscle fibers of *mdx* mice are more vulnerable to exercise than those of normal mice. *Neuromuscul Disord* 7:487-492

- Brunner S**, Kim JO, Methe H (2010) Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14⁺ monocytes to progression of coronary artery disease. *Am J Cardiol* 105:429-434
- Bulfield G**, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy *mdx* in the mouse. *Proc Natl Acad Sci USA* 81:1189-1192
- Burton EA**, Tinsley JM, Holzfeind PJ, Rodrigues NR, Davies KE (1999) A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. *Proc Natl Acad Sci USA* 96:14025-14030
- Bushby K**, Lochmuller H, Lynn S, Straub V (2009) Interventions for muscular dystrophy: molecular medicines entering the clinic. *Lancet* 374:1849-1856
- Buyse GM**, Van der Mieren G, Erb M, D'hooge J, Herijgers P, Verbeken E, Jara A, Van Den Bergh A, Mertens L, Courdier-Fruh I, Barzaghi P, and Meier T (2009) Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient *mdx* mouse: cardiac protection and improved exercise performance. *Eur. Heart J* 30:116-124
- Cacchiarelli D**, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, Nicoletti C, Santini T, Sthandier O, Barberi L, Auricchio A, Musaro A, Bozzoni I (2010) MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. *Cell Metab* 12:341-351
- Call JA**, Ervasti JM, Lowe DA (2011) TAT-muUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice. *J Appl Physiol* 111:200-205
- Call JA**, McKeehen JN, Novotny SA, Lowe DA (2010) Progressive resistance voluntary wheel running in the *mdx* mouse. *Muscle Nerve* 42:871-880
- Carter GT**, Abresch RT, Fowler WM, Jr. (2002) Adaptations to exercise training and contraction-induced muscle injury in animal models of muscular dystrophy. *Am J Phys Med Rehabil* 81:S151-S161
- Carter GT**, Wineinger MA, Walsh SA, Horasek SJ, Abresch RT, Fowler WM, Jr. (1995) Effect of voluntary wheel-running exercise on muscles of the *mdx* mouse. *Neuromuscul Disord* 5:323-332
- Castellano G**, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M (2008) Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. *Clin Cancer Res* 14:7470-7480
- Chamberlain JS** (1997) Dystrophin levels required for genetic correction of duchenne muscular dystrophy. *Basic and Applied Myology* 7:251-255
- Chamberlain JS**, Metzger J, Reyes M, Townsend D, Faulkner JA (2007) Dystrophin-deficient *mdx* mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. *FASEB J* 21:2195-2204
- Chan S**, Head SI (2011) The role of branched fibres in the pathogenesis of Duchenne muscular dystrophy. *Exp Physiol* 96:564-571
- Chan S**, Head SI, Morley JW (2007) Branched fibers in dystrophic *mdx* muscle are associated with a loss of force following lengthening contractions. *Am J Physiol Cell Physiol* 293:C985-C992
- Chapillon P**, Lalonde R, Jones N, Caston J (1998) Early development of synchronized walking on the rotarod in rats. Effects of training and handling. *Behav Brain Res* 93:77-81
- Chapman VM**, Miller DR, Armstrong D, Caskey CT (1989) Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. *Proc Natl Acad Sci USA* 86:1292-1296
- Chelly J**, Marlhens F, Le MB, Jeanpierre M, Lambert M, Hamard G, Dutrillaux B, Kaplan JC (1986) De novo DNA microdeletion in a girl with Turner syndrome and Duchenne muscular dystrophy. *Hum Genet* 74:193-196
- Chen YW**, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. *Neurology* 65:826-834
- Chen YW**, Zhao P, Borup R, Hoffman EP (2000) Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. *J Cell Biol* 151:1321-1336
- Chun JL**, O'Brien R, Berry SE (2012) Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy. *Neuromuscul Disord* 22:368-379
- Cirak S**, Arechavala-Gomez V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *Lancet* 378:595-605
- Clerk A**, Morris GE, Dubowitz V, Davies KE, Sewry CA (1993) Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. *Histochem J* 25:554-561

- Connolly AM**, Keeling RM, Mehta S, Pestronk A, Sanes JR (2001) Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. *Neuromuscul Disord* 11:703-712
- Connuck DM**, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, Wilkinson JD, Orav EJ, Cuniberti L, Salbert BA, and Lipshultz SE (2008) Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry *Am Heart J* 155:998-1005
- Consolino CM**, Brooks SV (2004) Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of *mdx* mice. *J Appl Physiol* 96:633-638
- Costa MF**, Oliveira AG, Feitosa-Santana C, Zatz M, Ventura DF (2007) Red-green color vision impairment in Duchenne muscular dystrophy. *Am J Hum Genet* 80:1064-1075
- Costas JM**, Nye DJ, Henley JB, Plochocki JH (2010) Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice. *Muscle Nerve* 42:881-885
- Cox GA**, Phelps SF, Chapman VM, Chamberlain JS (1993) New *mdx* mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. *Nat Genet* 4:87-93
- Crisp A**, Yin H, Goyenville A, Betts C, Moulton HM, Seow Y, Babbs A, Merritt T, Saleh AF, Gait MJ, Stuckey DJ, Clarke K, Davies KE, Wood MJ (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. *Hum Mol Genet* 20:413-421
- Danko I**, Chapman V, Wolff JA (1992) The frequency of revertants in *mdx* mouse genetic models for Duchenne muscular dystrophy. *Pediatr Res* 32:128-131
- De Luca A**, Nico B, Liantonio A, Didonna MP, Fraysse B, Pierro S, Burdi R, Mangieri D, Rolland JF, Camerino C, Zallone A, Confalonieri P, Andreetta F, Arnoldi E, Courdier-Fruh I, Magyar JP, Frigeri A, Pisoni M, Svelto M, Conte CD (2005) A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic *mdx* mice. *Am J Pathol* 166:477-489
- De Luca A**, Nico B, Rolland JF, Cozzoli A, Burdi R, Mangieri D, Giannuzzi V, Liantonio A, Cippone V, De Bellis M, Nicchia GP, Camerino GM, Frigeri A, Svelto M, Camerino DC (2008) Gentamicin treatment in exercised *mdx* mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. *Neurobiol Dis* 32:243-253
- De Luca A**, Pierro S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Ruegg UT, Conte CD (2003) Enhanced dystrophic progression in *mdx* mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. *J Pharmacol Exp Ther* 304:453-463
- De Paiva CS**, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, Pflugfelder SC (2006) Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. *Exp Eye Res* 83:526-535
- Deconinck AE**, Potter AC, Tinsley JM, Wood SJ, Vater R, Young C, Metzinger L, Vincent A, Slater CR, Davies KE (1997a) Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. *J Cell Biol* 136:883-894
- Deconinck AE**, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE (1997b) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. *Cell* 90:717-727
- Deconinck N**, Dan B (2007) Pathophysiology of duchenne muscular dystrophy: current hypotheses. *Pediatr Neurol* 36:1-7
- Deconinck N**, Rafael JA, Beckers-Bleukx G, Kahn D, Deconinck AE, Davies KE, Gillis JM (1998) Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. *Neuromuscul Disord* 8:362-370
- Deconinck N**, Tinsley J, De BF, Fisher R, Kahn D, Phelps S, Davies K, Gillis JM (1997c) Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. *Nat Med* 3:1216-1221
- den Dunnen JT**, Grootsholten PM, Bakker E, Blonden LA, Ginjaar HB, Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van Ommen GJ (1989) Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. *Am J Hum Genet* 45:835-847
- Dellorusso C**, Crawford RW, Chamberlain JS, Brooks SV (2001) Tibialis anterior muscles in *mdx* mice are highly susceptible to contraction-induced injury. *J Muscle Res Cell Motil* 22:467-475
- Dennis CL**, Tinsley JM, Deconinck AE, Davies KE (1996) Molecular and functional analysis of the utrophin promoter. *Nucleic Acids Res* 24:1646-1652

- Duchenne GB** (1868) Recherches sur la paralysie musculaire pseudohypertrophique ou paralysie myo-sclérosique. Arch Gen Med 11:178, 305, 421, 552
- Dunant P**, Laroche N, Thirion C, Stucka R, Ursu D, Petrof BJ, Wolf E, Lochmuller H (2003) Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic *mdx* mice. Mol Ther 8:80-89
- Dunkley MG**, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured *mdx* muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7:1083-1090
- Dupont-Versteegden EE**, McCarter RJ, Katz MS (1994) Voluntary exercise decreases progression of muscular dystrophy in diaphragm of *mdx* mice. J Appl Physiol 77:1736-1741
- Eagle M**, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K (2007) Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17:470-475
- Ehmsen J**, Poon E, Davies K (2002) The dystrophin-associated protein complex. J Cell Sci 115:2801-2803
- Emery AE** (1993) Duchenne muscular dystrophy--Meryon's disease. Neuromuscul Disord 3:263-266
- Emery AE**, Muntoni F (2003) Duchenne Muscular Dystrophy. Oxford University Press USA; 3rd edition
- England SB**, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343:180-182
- Faist V**, König J, Hoyer H, Elmadfa I (2001) Decreased mitochondrial oxygen consumption and antioxidant enzyme activities in skeletal muscle of dystrophic mice after low-intensity exercise. Ann Nutr Metab 45:58-66
- Ferretti R**, Neto HS, Marques MJ (2011) Expression of utrophin at dystrophin-deficient neuromuscular synapses of *mdx* mice: a study of protected and affected muscles. Anat Rec (Hoboken) 294:283-286
- Ferrier P**, Bamatter F, Klein D (1965) Muscular dystrophy (Duchenne) in a girl with Turner's syndrome. J Med Genet 2:38-46
- Finsterer J**, Stollberger C (2003) The heart in human dystrophinopathies. Cardiology 99:1-19
- Garrod P**, Hollingsworth KG, Eagle M, Aribisala BS, Birchall D, Bushby K, Straub V (2009) MR imaging in Duchenne muscular dystrophy: quantification of T1-weighted signal, contrast uptake, and the effects of exercise. J Magn Reson Imaging 30:1130-1138
- Ghedini PC**, Viel TA, Honda L, Avellar MC, Godinho RO, Lima-Landman MT, Lapa AJ, Souccar C (2008) Increased expression of acetylcholine receptors in the diaphragm muscle of *mdx* mice. Muscle Nerve 38:1585-1594
- Goemans NM**, Tulinius M, van den Akker JT, Burm BE, Ekhardt PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364:1513-1522
- Goleva E**, Hauk PJ, Boguniewicz J, Martin RJ, Leung DY (2007) Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 120:1065-1072
- Golumbek PT**, Keeling RM, Connolly AM (2007) Strength and corticosteroid responsiveness of *mdx* mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 17:376-384
- Gorecki DC**, Monaco AP, Derry JM, Walker AP, Barnard EA, Barnard PJ (1992) Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet 1:505-510
- Gowers WE** (1879) Pseudo-hypertrophic muscular paralysis. A clinical lecture. J. & A. Churchill, New Burlington street, London
- Goyenvalle A**, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD, Davies KE (2010) Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18:198-205
- Goyenvalle A**, Babbs A, Wright J, Wilkins V, Powell D, Garcia L, Davies KE (2012) Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet
- Grady RM**, Merlie JP, Sanes JR (1997a) Subtle neuromuscular defects in utrophin-deficient mice. J Cell Biol 136:871-882
- Grady RM**, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR (1997b) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90:729-738
- Grady RM**, Zhou H, Cunningham JM, Henry MD, Campbell KP, Sanes JR (2000) Maturation and maintenance of the neuromuscular synapse: genetic evidence for roles of the dystrophin--glycoprotein complex. Neuron 25:279-293
- Granchelli JA**, Pollina C, Hudecki MS (2000) Pre-clinical screening of drugs using the *mdx* mouse. Neuromuscul Disord 10:235-239

- Gregorevic P**, Mezmarich NA, Blankinship MJ, Crawford RW, Chamberlain JS (2008) Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. *Muscle Nerve* 37:104-106
- Grounds MD**, Radley HG, Lynch GS, Nagaraju K, De Luca A (2008) Towards developing standard operating procedures for pre-clinical testing in the *mdx* mouse model of Duchenne muscular dystrophy. *Neurobiol Dis* 31:1-19
- Grounds MD**, Shavlakadze T (2011) Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders. *Bioessays* 33:458-468
- Gulati S**, Saxena A, Kumar V, and Kalra V (2005) Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. *Indian J Pediatr* 72:389-393
- Haenggi T**, Fritschy JM (2006) Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. *Cell Mol Life Sci* 63:1614-1631
- Hainsey TA**, Senapati S, Kuhn DE, Rafael JA (2003) Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovascular. *Neuromuscul Disord* 13:294-302
- Hakim CH**, Duan D (2012) Gender differences in contractile and passive properties of *mdx* extensor digitorum longus muscle. *Muscle Nerve* 45:250-256
- Hara H**, Nolan PM, Scott MO, Bucan M, Wakayama Y, Fischbeck KH (2002) Running endurance abnormality in *mdx* mice. *Muscle Nerve* 25:207-211
- Haslett JN**, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel LM (2002) Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. *Proc Natl Acad Sci USA* 99:15000-15005
- Hauser MA**, Amalfitano A, Kumar-Singh R, Hauschka SD, Chamberlain JS (1997) Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. *Neuromuscul Disord* 7:277-283
- Hayes A**, Williams DA (1996) Beneficial effects of voluntary wheel running on the properties of dystrophic mouse muscle. *J Appl Physiol* 80:670-679
- Hayes A**, Williams DA (1998) Contractile function and low-intensity exercise effects of old dystrophic *mdx* mice. *Am J Physiol* 274:C1138-C1144
- Head SI**, Williams DA, Stephenson DG (1992) Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic *mdx* mice. *Proc Biol Sci* 248:163-169
- Heemskerk HA**, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A (2009) In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. *J Gene Med* 11:257-266
- Heemskerk H**, de Winter CL, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, Braghetta P, van Ommen GJ, de Kimpe S, Ferlini A, Aartsma-Rus A, van Deutekom JC (2010) Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the *mdx* mouse model. *Mol Ther* 18:1210-1217
- Heemskerk H**, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A (2009) Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. *Ann N Y Acad Sci* 1175:71-79
- Helderman-van den Enden A**, Straathof CS, Aartsma-Rus A, den Dunnen JT, Verbist BM, Bakker E, Verschuuren JJ, Ginjaar HB (2010) Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. *Neuromuscul Disord* 20:251-254
- Hernandez-Gonzalez EO**, Mornet D, Rendon A, Martinez-Rojas D (2005) Absence of Dp71 in *mdx^{2cv}* mouse spermatozoa alters flagellar morphology and the distribution of ion channels and nNOS. *J Cell Sci* 118:137-145
- Hirawat S**, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. *J Clin Pharmacol* 47:430-444
- Hoffman EP**, Brown RH, Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 51:919-928
- Hoffman EP**, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L (1988) Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. *N Engl J Med* 318:1363-1368
- Hoffman EP**, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB (1989) Improved diagnosis of Becker muscular dystrophy by dystrophin testing. *Neurology* 39:1011-1017

- Hoffman EP**, Morgan JE, Watkins SC, Partridge TA (1990) Somatic reversion/suppression of the mouse *mdx* phenotype in vivo. *J Neurol Sci* 99:9-25
- Holmes KC** (1996) Muscle proteins--their actions and interactions. *Curr Opin Struct Biol* 6:781-789
- Hoogerwaard EM**, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, Van Essen AJ, Brunner HG, van der Wouw PA, Wilde AA, de Visser M (1999) Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. *Lancet* 353:2116-2119
- Howard PL**, Dally GY, Wong MH, Ho A, Weleber RG, Pillers DA, Ray PN (1998) Localization of dystrophin isoform Dp71 to the inner limiting membrane of the retina suggests a unique functional contribution of Dp71 in the retina. *Hum Mol Genet* 7:1385-1391
- Huang P**, Cheng G, Lu H, Aronica M, Ransohoff RM, Zhou L (2011) Impaired respiratory function in *mdx* and *mdx/utrn*^{+/-} mice. *Muscle Nerve* 43:263-267
- Hurst JW** (1998) Naming of the waves in the ECG, with a brief account of their genesis. *Circulation* 98:1937-1942
- Im WB**, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS (1996) Differential expression of dystrophin isoforms in strains of *mdx* mice with different mutations. *Hum Mol Genet* 5:1149-1153
- Ishizaki M**, Suga T, Kimura E, Shiota T, Kawano R, Uchida Y, Uchino K, Yamashita S, Maeda Y, Uchino M (2008) *Mdx* respiratory impairment following fibrosis of the diaphragm. *Neuromuscul Disord* 18:342-348
- Janssen PM**, Hiranandani N, Mays TA, Rafael-Fortney JA (2005) Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient *mdx* mice. *Am J Physiol Heart Circ Physiol* 289:H2373-H2378
- Jearawiriyapaisarn N**, Moulton HM, Sazani P, Kole R, and Willis MS (2010) Long-term improvement in *mdx* cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. *Cardiovasc. Res.* 85:444-453.
- Johnson MA**, Polgar J, Weightman D, Appleton D (1973) Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. *J Neurol Sci* 18:111-129
- Kaja S**, Todorov B, van de Ven RC, Ferrari MD, Frants RR, van den Maagdenberg AM, Plomp JJ (2007) Redundancy of Cav2.1 channel accessory subunits in transmitter release at the mouse neuromuscular junction. *Brain Res* 1143:92-101
- Karpati G**, Carpenter S, Prescott S (1988) Small-caliber skeletal muscle fibers do not suffer necrosis in *mdx* mouse dystrophy. *Muscle Nerve* 11:795-803
- Karpati G**, Zubrzycka-Gaarn EE, Carpenter S, Bulman DE, Ray PN, Worton RG (1990) Age-related conversion of dystrophin-negative to -positive fiber segments of skeletal but not cardiac muscle fibers in heterozygote *mdx* mice. *J Neuropathol Exp Neurol* 49:96-105
- Kaspar RW**, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, Weiss RB, Flanigan KM, Mendell JR, and Montanaro F (2009). Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. *Circ. Cardiovasc. Genet.* 2, 544-551.
- Kawano R**, Ishizaki M, Maeda Y, Uchida Y, Kimura E, Uchino M (2008) Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice. *Mol Ther* 16:825-831
- Khurana TS**, Prendergast RA, Alameddine HS, Tome FM, Fardeau M, Arahata K, Sugita H, Kunkel LM (1995) Absence of extraocular muscle pathology in Duchenne's muscular dystrophy: role for calcium homeostasis in extraocular muscle sparing. *J Exp Med* 182:467-475
- Kinali M**, Arechavala-Gomez V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *Lancet Neurol* 8:918-928
- Klein CJ**, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH (1992) Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. *Am J Hum Genet* 50:950-959
- Kleopa KA**, Drousiotou A, Mavrikiou E, Ormiston A, Kyriakides T (2006) Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. *Hum Mol Genet* 15:1623-1628
- Knuesel I**, Bornhauser BC, Zuellig RA, Heller F, Schaub MC, Fritschy JM (2000) Differential expression of utrophin and dystrophin in CNS neurons: an in situ hybridization and immunohistochemical study. *J Comp Neurol* 422:594-611
- Kobayashi YM**, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV, Weiss RM, Chamberlain JS, Moore SA, Campbell KP (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. *Nature* 456:511-515

- Koenig M**, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. *Cell* 50:509-517
- Koenig M**, Kunkel LM (1990) Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. *J Biol Chem* 265:4560-4566
- Koenig M**, Monaco AP, Kunkel LM (1988) The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell* 53:219-228
- Kohler M**, Clarenbach CF, Boni L, Brack T, Russi EW, Bloch KE (2005) Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. *Am J Respir Crit Care Med* 172:1032-1036
- Kohler M**, Clarenbach CF, Bahler C, Brack T, Russi EW, Bloch KE (2009) Disability and survival in Duchenne muscular dystrophy. *J Neurol Neurosurg Psychiatry* 80:320-325
- Konhilas JP**, Widgren U, Allen DL, Paul AC, Cleary A, Leinwand LA (2005) Loaded wheel running and muscle adaptation in the mouse. *Am J Physiol Heart Circ Physiol* 289:H455-H465
- Lai Y**, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, Duan D (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. *J Clin Invest* 119:624-635
- Landisch RM**, Kosir AM, Nelson SA, Baltgalvis KA, Lowe DA (2008) Adaptive and nonadaptive responses to voluntary wheel running by *mdx* mice. *Muscle Nerve* 38:1290-1303
- Law DJ**, Tidball JG (1993) Dystrophin deficiency is associated with myotendinous junction defects in pre necrotic and fully regenerated skeletal muscle. *Am J Pathol* 142:1513-1523
- Lee CC**, Pons F, Jones PG, Bies RD, Schlang AM, Leger JJ, Caskey CT (1993) *Mdx* transgenic mouse: restoration of recombinant dystrophin to the dystrophic muscle. *Hum Gene Ther* 4:273-281
- Lewis C**, Ohlendieck K (2010) Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient *mdx* mouse. *Biochem Biophys Res Commun* 396:1024-1029
- Li D**, Yue Y, Duan D (2008) Preservation of muscle force in *Mdx^{scv}* mice correlates with low-level expression of a near full-length dystrophin protein. *Am J Pathol* 172:1332-1341
- Li D**, Yue Y, Duan D (2010) Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. *PLoS One* 5:e15286
- Li H**, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A (2009) Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. *Hum Mol Genet* 18:2584-2598
- Li W**, Liu W, Zhong J, Yu X (2009) Early manifestation of alteration in cardiac function in dystrophin deficient *mdx* mouse using 3D CMR tagging. *J Cardiovasc Magn Reson* 11:40
- Lidov HG** (1996) Dystrophin in the nervous system. *Brain Pathol* 6:63-77
- Lindenbaum RH**, Clarke G, Patel C, Moncrieff M, Hughes JT (1979) Muscular dystrophy in an X; 1 translocation female suggests that Duchenne locus is on X chromosome short arm. *J Med Genet* 16:389-392
- Lo Mauro A**, D'Angelo MG, Romei M, Motta F, Colombo D, Comi GP, Pedotti A, Marchi E, Turconi AC, Bresolin N, Aliverti A (2010) Abdominal volume contribution to tidal volume as an early indicator of respiratory impairment in Duchenne muscular dystrophy. *Eur Respir J* 35:1118-1125
- Love DR**, Forrest SM, Smith TJ, England S, Flint T, Davies KE, Speer A (1989a) Molecular analysis of Duchenne and Becker muscular dystrophies. *Br Med Bull* 45:659-680
- Love DR**, Hill DF, Dickson G, Spurr NK, Byth BC, Marsden RF, Walsh FS, Edwards YH, Davies KE (1989b) An autosomal transcript in skeletal muscle with homology to dystrophin. *Nature* 339:55-58
- Lovering RM**, Michaelson L, Ward CW (2009) Malformed *mdx* myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca²⁺ signaling. *Am J Physiol Cell Physiol* 297:C571-C580
- Lu QL**, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the *mdx* dystrophic mouse. *Nat Med* 9:1009-1014
- Lu QL**, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P, Partridge TA (2000) Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. *J Cell Biol* 148:985-996
- Lu QL**, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. *Proc Natl Acad Sci USA* 102:198-203
- Lupski JR**, Garcia CA, Zoghbi HY, Hoffman EP, Fenwick RG (1991) Discordance of muscular dystrophy in monozygotic female twins: evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of Duchenne dystrophy. *Am J Med Genet* 40:354-364

- Lynch GS**, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA (2001) Force and power output of fast and slow skeletal muscles from *mdx* mice 6-28 months old. *J Physiol* 535:591-600
- Lyon M** (1961) Gene action in the X-chromosome of the mouse (*Mus musculus* L.). *Nature* 190:372-373
- Lyons PR**, Slater CR (1991) Structure and function of the neuromuscular junction in young adult *mdx* mice. *J Neurocytol* 20:969-981
- Maciver DH**, Townsend M (2008) A novel mechanism of heart failure with normal ejection fraction. *Heart* 94:446-449
- Malerba A**, Boldrin L, Dickson G (2011a) Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. *Nucleic Acid Ther* 21:293-298
- Malerba A**, Sharp PS, Graham IR, Arechavala-Gomez V, Foster K, Muntoni F, Wells DJ, Dickson G (2011b) Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in *mdx* mice. *Mol Ther* 19:345-354
- Malerba A**, Thorogood FC, Dickson G, Graham IR (2009) Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in *mdx* mice. *Hum Gene Ther* 20:955-965
- Malik V**, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano-Munuera C, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. *Ann Neurol* 67:771-780
- Manzur AY**, Kinali M, Muntoni F (2008) Update on the management of Duchenne muscular dystrophy. *Arch Dis Child* 93:986-990
- Marden FA**, Connolly AM, Siegel MJ, Rubin DA (2005) Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. *Skeletal Radiol* 34:140-148
- Marshall PA**, Williams PE, Goldspink G (1989) Accumulation of collagen and altered fiber-type ratios as indicators of abnormal muscle gene expression in the *mdx* dystrophic mouse. *Muscle Nerve* 12:528-537
- Martigne L**, Salleron J, Mayer M, Cuisset JM, Carpentier A, Neve V, Tiffreau V, Guimber D, Gottrand F (2011) Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. *Br.J.Nutr.* 105:1486-1491
- Matsumura T**, Saito T, Fujimura H, and Shinno S (2007). Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. *Brain Dev.* 29, 496-501.
- Mazzone ES**, Messina S, Vasco G, Main M, Eagle M, D'Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Magri F, Corlatti A, Zucchini E, Brancalione B, Rossi F, Ferretti M, Motta MG, Cecio MR, Berardinelli A, Alfieri P, Mongini T, Pini A, Astrea G, Battini R, Comi G, Pegoraro E, Morandi L, Pane M, Angelini C, Bruno C, Villanova M, Vita G, Donati MA, Bertini E, Mercuri E (2009) Reliability of the North Star Ambulatory Assessment in a multicentric setting. *Neuromuscul Disord* 19:458-461
- Melacini P**, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, Freda MP, Miorelli M, Mostacciolo ML, Fasoli G, Angelini C, and Dalla VS (1996). Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. *Circulation* 94, 3168-3175.
- Melis MA**, Cau M, Muntoni F, Mateddu A, Galanello R, Boccone L, Deidda F, Loi D, Cao A (1998) Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. *Eur J Paediatr Neurol* 2:255-261
- Mendell JR**, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM (2010) Dystrophin immunity in Duchenne's muscular dystrophy. *N Engl J Med* 363:1429-1437
- Meryon E** (1852) On Granular and Fatty Degeneration of the Voluntary Muscles. *Med Chir Trans* 35:73-84
- Miike T**, Miyatake M, Zhao J, Yoshioka K, Uchino M (1989) Immunohistochemical dystrophin reaction in synaptic regions. *Brain Dev* 11:344-346
- Miike T**, Sugino S, Ohtani Y, Taku K, Yoshioka K (1987) Vascular endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the preclinical stage. *J Neurol Sci* 82:67-80
- Minetti GC**, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, Straino S, Sampaioles M, Di PM, Illi B, Gallinari P, Steinkuhler C, Capogrossi MC, Sartorelli V, Bottinelli R, Gaetano C, Puri PL (2006) Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. *Nat Med* 12:1147-1150
- Mirowska D**, Wicha W, Czlonkowska A, Czlonkowska A, Weber F (2004) Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. *J Neuroimmunol* 146:171-175

- Mizuno Y**, Nonaka I, Hirai S, Ozawa E (1993) Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. *J Neurol Sci* 119:43-52
- Monaco AP**, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics* 2:90-95
- Moulton HM**, Wu B, Jearawiriyapaisarn N, Sazani P, Lu QL, Kole R (2009) Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. *Ann N Y Acad Sci* 1175:55-60
- Muntoni F**, Mateddu A, Marchei F, Clerk A, Serra G (1993) Muscular weakness in the *mdx* mouse. *J Neurol Sci* 120:71-77
- Muntoni F**, Torelli S, Brockington M (2008) Muscular dystrophies due to glycosylation defects. *Neurotherapeutics* 5:627-632
- Muntoni F**, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol* 2:731-740
- Mysliwiec J**, Adamczyk M, Pawlowski P, Nikolajuk A, Gorska M (2007) Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy. *Endokrynol Pol* 58:105-109
- Nadarajah VD**, van Putten M, Chaouch A, Garrood P, Straub V, Lochmuller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJ, den Dunnen JT, 't Hoen PA (2011) Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). *Neuromuscul Disord* 21:569-578
- Nakamura A**, Yoshida K, Takeda S, Dohi N, Ikeda S (2002) Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of *mdx* mice. *FEBS Lett* 520:18-24
- Narita S**, Yorifuji H (1999) Centrally nucleated fibers (CNFs) compensate the fragility of myofibers in *mdx* mouse. *Neuroreport* 10:3233-3235
- Neri M**, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, Spitali P, Rimessi P, Gualandi F, Sewry C, Ferlini A, Muntoni F (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. *Neuromuscul Disord* 17:913-918
- Newall AE**, Duthie S, Formstone E, Nesterova T, Alexiou M, Johnston C, Caparros ML, Brockdorff N (2001) Primary non-random X inactivation associated with disruption of Xist promoter regulation. *Hum Mol Genet* 10:581-589
- Ng K**, Pullirsch D, Leeb M, Wutz A (2007) Xist and the order of silencing. *EMBO Rep* 8:34-39
- Nguyen TM**, Ellis JM, Love DR, Davies KE, Gatter KC, Dickson G, Morris GE (1991) Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. *J Cell Biol* 115:1695-1700
- Nicholson LV**, Johnson MA, Bushby KM, Gardner-Medwin D (1993) Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. *Arch Dis Child* 68:632-636
- Nigro G**, Comi LI, Politano L, and Bain RJ (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int. J. Cardiol.* 26, 271-277.
- Oda T**, Shimizu N, Yonenobu K, Ono K, Nabeshima T, Kyoh S (1993) Longitudinal study of spinal deformity in Duchenne muscular dystrophy. *J Pediatr Orthop* 13:478-488
- Ogata H**, Nakagawa H, Hamabe K, Hattori A, Ishikawa Y, Ishikawa Y, Saito M, Minami R (2000) A female carrier of Duchenne muscular dystrophy complicated with cardiomyopathy. *Intern Med* 39:34-38
- Ohlendieck K**, Ervasti JM, Matsumura K, Kahl SD, Leveille CJ, Campbell KP (1991) Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. *Neuron* 7:499-508
- Payne ET**, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J, Tarnopolsky MA (2006) Nutritional therapy improves function and complements corticosteroid intervention in *mdx* mice. *Muscle Nerve* 33:66-77
- Pearce M**, Blake DJ, Tinsley JM, Byth BC, Campbell L, Monaco AP, Davies KE (1993) The utrophin and dystrophin genes share similarities in genomic structure. *Hum Mol Genet* 2:1765-1772
- Pegoraro E**, Hoffman EP, Piva L, Gavassini BF, Cagnin S, Ermani M, Bello L, Soraru G, Pacchioni B, Bonifati MD, Lanfranchi G, Angelini C, Kesari A, Lee I, Gordish-Dressman H, Devaney JM, McDonald CM (2011) SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. *Neurology* 76:219-226
- Pegoraro E**, Schimke RN, Garcia C, Stern H, Cadaldini M, Angelini C, Barbosa E, Carroll J, Marks WA, Neville HE, Marks H, Appleton S, Toriello H, Wessel HB, Donnelly J, Bernes SM, Taber JW, Weiss L, Hoffman EP (1995) Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. *Neurology* 45:677-690

- Perkins KJ**, Davies KE (2002) The role of utrophin in the potential therapy of Duchenne muscular dystrophy. *Neuromuscul Disord* 12 Suppl 1:S78-S89
- Perronnet C**, Vaillend C (2010) Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies. *J Biomed Biotechnol* 2010:849426
- Pescatori M**, Broccolini A, Minetti C, Bertini E, Bruno C, D'Amico A, Bernardini C, Mirabella M, Silvestri G, Giglio V, Modoni A, Pedemonte M, Tasca G, Galluzzi G, Mercuri E, Tonali PA, Ricci E (2007) Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. *FASEB J* 21:1210-1226
- Phelps SF**, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic *mdx* mice. *Hum Mol Genet* 4:1251-1258
- Pierno S**, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V, Frayssé B, Rolland JF, Mangieri D, Andreetta F, Ferro P, Camerino C, Zallone A, Confalonieri P, De Luca A (2007) Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in *mdx* mice: a pharmacological approach. *Neuropathol Appl Neurobiol* 33:344-359
- Pilgram GS**, Potikanond S, Baines RA, Fradkin LG, Noordermeer JN (2010) The roles of the dystrophin-associated glycoprotein complex at the synapse. *Mol Neurobiol* 41:1-21
- Pillars DA**, Fitzgerald KM, Duncan NM, Rash SM, White RA, Dwinnell SJ, Powell BR, Schnur RE, Ray PN, Cibis GW, Weleber RG (1999) Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations. *Hum Genet* 105:2-9
- Pillars DA**, Weleber RG, Woodward WR, Green DG, Chapman VM, Ray PN (1995) *mdx*^{cvs} mouse is a model for electroretinography of Duchenne/Becker muscular dystrophy. *Invest Ophthalmol Vis Sci* 36:462-466
- Pons F**, Nicholson LV, Robert A, Voit T, Leger JJ (1993) Dystrophin and dystrophin-related protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. *Neuromuscul Disord* 3:507-514
- Porter JD** (1998) Commentary: extraocular muscle sparing in muscular dystrophy: a critical evaluation of potential protective mechanisms. *Neuromuscul Disord* 8:198-203
- Porter JD**, Rafael JA, Ragusa RJ, Brueckner JK, Trickett JI, Davies KE (1998) The sparing of extraocular muscle in dystrophinopathy is lost in mice lacking utrophin and dystrophin. *J Cell Sci* 111 (Pt 13):1801-1811
- Quinlan JG**, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, and Levin LS (2004). Evolution of the *mdx* mouse cardiomyopathy: physiological and morphological findings. *Neuromuscul Disord* 14, 491-496.
- Radley HG**, Davies MJ, Grounds MD (2008) Reduced muscle necrosis and long-term benefits in dystrophic *mdx* mice after cV1q (blockade of TNF) treatment. *Neuromuscul Disord* 18:227-238
- Radley HG**, Grounds MD (2006) Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in *mdx* mice. *Neurobiol Dis* 23:387-397
- Rafael JA**, Sunada Y, Cole NM, Campbell KP, Faulkner JA, Chamberlain JS (1994) Prevention of dystrophic pathology in *mdx* mice by a truncated dystrophin isoform. *Hum Mol Genet* 3:1725-1733
- Rafael JA**, Tinsley JM, Potter AC, Deconinck AE, Davies KE (1998) Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. *Nat Genet* 19:79-82
- Rafael JA**, Townsend ER, Squire SE, Potter AC, Chamberlain JS, Davies KE (2000) Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. *Hum Mol Genet* 9:1357-1367
- Rafael JA**, Trickett JI, Potter AC, Davies KE (1999) Dystrophin and utrophin do not play crucial roles in nonmuscle tissues in mice. *Muscle Nerve* 22:517-519
- Rafael-Fortney JA**, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfin DA, Janssen PM, Raman SV (2011) Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice. *Circulation* 124:582-588
- Raffetto JD**, Khalil RA (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. *Biochem Pharmacol* 75:346-359
- Ramakers C**, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci Lett* 339:62-66
- Raymackers JM**, Debaix H, Colson-Van SM, De Backer F, Tajeddine N, Schwaller B, Gailly P, Gillis JM (2003) Consequence of parvalbumin deficiency in the *mdx* mouse: histological, biochemical and mechanical phenotype of a new double mutant. *Neuromuscul Disord* 13:376-387
- Richards CS**, Watkins SC, Hoffman EP, Schneider NR, Milsark IW, Katz KS, Cook JD, Kunkel LM, Cortada JM (1990) Skewed X inactivation in a female MZ twin results in Duchenne muscular dystrophy. *Am J Hum Genet* 46:672-681
- Rifai N**, Gillette NA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nat Biotechnol* 24:971-983

- Roberts RG**, Coffey AJ, Bobrow M, Bentley DR (1993) Exon structure of the human dystrophin gene. *Genomics* 16:536-538
- Ruifrok AC**, Katz RL, Johnston DA (2003) Comparison of quantification of histochemical staining by hue-saturation-intensity (HSI) transformation and color-deconvolution. *Appl Immunohistochem Mol Morphol* 11:85-91
- Rybakova IN**, Amann KJ, Ervasti JM (1996) A new model for the interaction of dystrophin with F-actin. *J Cell Biol* 135:661-672
- Saito T**, Yamamoto Y, Matsumura T, Nozaki S, Fujimura H, Shinno S (2005) Coagulation system activated in Duchenne muscular dystrophy patients with cardiac dysfunction. *Brain Dev* 27:415-418
- Saito T**, Yamamoto Y, Matsumura T, Fujimura H, Shinno S (2009) Serum levels of vascular endothelial growth factor elevated in patients with muscular dystrophy. *Brain Dev* 31:612-617
- Sander M**, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG (2000) Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. *Proc Natl Acad Sci USA* 97:13818-13823
- Sazani P**, Blouch R, Weller D, Leow S, Kole R, Shrewsbury SB (2009) AVI 5038: Initial efficacy and safety evaluation in cynomolgus monkeys. Treat-NMD/NIH Conference
- Schade van Westrum, SM**, Dekker L, Endert E, de Haan RJ, Wilde AAM, de Visser M, and van der Kooi AJ (2006) NT-proBNP is not associated with dilated cardiomyopathy in Becker and Duchenne muscular dystrophies. *Neuromuscul Disord Ref Type: Abstract*
- Schiaffino S**, Gorza L, Sartore S, Saggin L, Ausoni S, Vianello M, Gundersen K, Lomo T (1989) Three myosin heavy chain isoforms in type 2 skeletal muscle fibres. *J Muscle Res Cell Motil* 10:197-205
- Schmidt-Achert M**, Fischer P, Muller-Felber W, Mudra H, Pongratz D (1993) Heterozygotic gene expression in endomyocardial biopsies: a new diagnostic tool confirms the Duchenne carrier status. *Clin Investig* 71:247-253
- Schneider JE**, Cassidy PJ, Lygate C, Tyler DJ, Wiesmann F, Grieve SM, Hulbert K, Clarke K, Neubauer S (2003) Fast, high-resolution in vivo cine magnetic resonance imaging in normal and failing mouse hearts on a vertical 11.7 T system. *J Magn Reson Imaging* 18:691-701
- Sciandra F**, Bozzi M, Bianchi M, Pavoni E, Giardina B, Brancaccio A (2003) Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex. *Ann Ist Super Sanita* 39:173-181
- Senner CE**, Brockdorff N (2009) Xist gene regulation at the onset of X inactivation. *Curr Opin Genet Dev* 19:122-126
- Sharp PS**, Jee H, Wells DJ (2011) Physiological characterization of muscle strength with variable levels of dystrophin restoration in *mdx* mice following local antisense therapy. *Mol Ther* 19:165-171
- Sicinski P**, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ (1989) The molecular basis of muscular dystrophy in the *mdx* mouse: a point mutation. *Science* 244:1578-1580
- Skuk D**, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, Dugre FJ, Sylvain M, Lachance JG, Deschenes L, Senay H, Tremblay JP (2006) Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. *J Neuropathol Exp Neurol* 65:371-386
- Skuk D**, Goulet M, Roy B, Piette V, Cote CH, Chapdelaine P, Hogrel JY, Paradis M, Bouchard JP, Sylvain M, Lachance JG, and Tremblay JP (2007) First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. *Neuromuscul Disord* 17:38-46
- Soltanzadeh P**, Friez MJ, Dunn D, von NA, Gurvich OL, Swoboda KJ, Sampson JB, Pestronk A, Connolly AM, Florence JM, Finkel RS, Bonnemann CG, Medne L, Mendell JR, Mathews KD, Wong BL, Sussman MD, Zonana J, Kovak K, Gospe SM, Jr, Gappmaier E, Taylor LE, Howard MT, Weiss RB, Flanigan KM (2010) Clinical and genetic characterization of manifesting carriers of DMD mutations. *Neuromuscul Disord* 20:499-504
- Spurney CF**, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, van der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K (2009) Preclinical drug trials in the *mdx* mouse: assessment of reliable and sensitive outcome measures. *Muscle Nerve* 39:591-602
- Spurney CF**, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP (2008) Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. *Neuromuscul Disord* 18:371-381
- Squire S**, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, Fisher R, Gillis JM, Davies KE (2002) Prevention of pathology in *mdx* mice by expression of utrophin: analysis using an inducible transgenic expression system. *Hum Mol Genet* 11:3333-3344
- Stedman HH**, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM (1991) The *mdx* mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. *Nature* 352:536-539

- Stillwell E**, Vitale J, Zhao Q, Beck A, Schneider J, Khadim F, Elson G, Altaf A, Yehia G, Dong JH, Liu J, Mark W, Bhaumik M, Grange R, Fraidenraich D (2009) Blastocyst injection of wild type embryonic stem cells induces global corrections in *mdx* mice. *PLoS One* 4:e4759
- Summerton J**, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. *Antisense Nucleic Acid Drug Dev* 7:187-195
- Sun G**, Haginoya K, Chiba Y, Uematsu M, Hino-Fukuyo N, Tanaka S, Onuma A, Iinuma K, Tsuchiya S (2010) Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy. *J Neurol Sci* 297:19-28
- Sun GL**, Zhao S, Li P, Jiang HK (2006) Expression of tissue inhibitor of metalloproteinase-1 in progression muscular dystrophy. *Neurosci Bull* 22:85-90
- Takeshima Y**, Wada H, Yagi M, Ishikawa Y, Ishikawa Y, Minami R, Nakamura H, Matsuo M (2001) Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. *Brain Dev* 23:788-790
- Tanaka H**, Ikeya K, Ozawa E (1990) Difference in the expression pattern of dystrophin on the surface membrane between the skeletal and cardiac muscles of *mdx* carrier mice. *Histochemistry* 93:447-452
- Tennyson CN**, Klamut HJ, Worton RG (1995) The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. *Nat Genet* 9:184-190
- Thanh LT**, Nguyen TM, Helliwell TR, Morris GE (1995) Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. *Am J Hum Genet* 56:725-731
- Thomas LB**, Joseph GL, Adkins TD, Andrade FH, Stemple JC (2008) Laryngeal muscles are spared in the dystrophin deficient *mdx* mouse. *J Speech Lang Hear Res* 51:586-595
- Tinsley J**, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies K (1998) Expression of full-length utrophin prevents muscular dystrophy in *mdx* mice. *Nat Med* 4:1441-1444
- Tinsley JM**, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE (1996) Amelioration of the dystrophic phenotype of *mdx* mice using a truncated utrophin transgene. *Nature* 384:349-353
- Torres LF**, Duchon LW (1987) The mutant *mdx*: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. *Brain* 110 (Pt 2):269-299
- Torriani M**, Townsend E, Thomas BJ, Bredella MA, Ghomi RH, Tseng BS (2011) Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. *Skeletal Radiol* 41:437-445
- Townsend D**, Yasuda S, Li S, Chamberlain JS, Metzger JM (2008) Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. *Mol Ther* 16:832-835
- Turgeman T**, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M (2008) Prevention of muscle fibrosis and improvement in muscle performance in the *mdx* mouse by halofuginone. *Neuromuscul Disord* 18:857-868
- Turk R**, Sterrenburg E, de Meijer EJ, van Ommen GJ, den Dunnen JT, 't Hoen PA (2005) Muscle regeneration in dystrophin-deficient *mdx* mice studied by gene expression profiling. *BMC Genomics* 6:98
- Turk R**, Sterrenburg E, van der Wees CG, de Meijer EJ, de Menezes RX, Groh S, Campbell KP, Noguchi S, van Ommen GJ, den Dunnen JT, 't Hoen PA (2006) Common pathological mechanisms in mouse models for muscular dystrophies. *FASEB J* 20:127-129
- Vaillend C**, Billard JM, Claudepierre T, Rendon A, Dutar P, Ungerer A (1998) Spatial discrimination learning and CA1 hippocampal synaptic plasticity in *mdx* and *mdx3cv* mice lacking dystrophin gene products. *Neuroscience* 86:53-66
- Vaillend C**, Rendon A, Misslin R, Ungerer A (1995) Influence of dystrophin-gene mutation on *mdx* mouse behavior. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks. *Behav Genet* 25:569-579
- Vaillend C**, Ungerer A (1999) Behavioral characterization of *mdx3cv* mice deficient in C-terminal dystrophins. *Neuromuscul Disord* 9:296-304
- van Bockel EA**, Lind JS, Zijlstra JG, Wijkstra PJ, Meijer PM, van den Berg MP, Slart RH, Aarts LP, and Tulleken JE (2009) Cardiac assessment of patients with late stage Duchenne muscular dystrophy. *Neth. Heart J* 17:232-237
- van der Geest RJ**, Buller VG, Jansen E, Lamb HJ, Baur LH, van der Wall EE, de RA, Reiber JH (1997) Comparison between manual and semiautomated analysis of left ventricular volume parameters from short-axis MR images. *J Comput Assist Tomogr* 21:756-765
- van der Geest RJ**, Reiber JH (1999) Quantification in cardiac MRI. *J Magn Reson Imaging* 10:602-608

- van Deutekom JC**, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. *Hum Mol Genet* 10:1547-1554
- van Deutekom JC**, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhardt PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. *N Engl J Med* 357:2677-2686
- van Erp C**, Loch D, Laws N, Trebbin A, Hoey AJ (2010) Timeline of cardiac dystrophy in 3-18-month-old *mdx* mice. *Muscle Nerve* 42:504-513
- van Putten M**, de Winter CL, van Roon-Mom W, van Ommen GJ, 't Hoen PA, Aartsma-Rus A (2010) A 3 months mild functional test regime does not affect disease parameters in young *mdx* mice. *Neuromuscul Disord* 20:273-280
- van Putten M**, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M, Admiraal P, Messemaker T, den Dunnen JT, 't Hoen PA, Aartsma-Rus A (2012a) The effects of low levels of dystrophin on mouse muscle function and pathology. *PLoS One* 7:e31937
- van Putten M**, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJ, 't Hoen PA, Aartsma-Rus A (2012b) Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. *Neuromuscul Disord* 5:406-417
- Verhaart IE**, Heemskerk H, Karnaoukh TG, Kolfshoten IG, Vroon A, van Ommen GJ, van Deutekom JC, Aartsma-Rus A (2012) Prednisolone Treatment Does Not Interfere with 2'-O-Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy. *Hum Gene Ther* 3:262-273
- Verhaart IE**, van Duijn RJ, den Adel B, Roest AA, Verschuuren JJ, Aartsma-Rus A, van der Weerd L (2011) Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. *Neuromuscul Disord* 5:418-426
- Vetrone SA**, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ (2009) Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. *J Clin Invest* 119:1583-1594
- Vilquin JT**, Brussee V, Asselin I, Kinoshita I, Gingras M, Tremblay JP (1998) Evidence of *mdx* mouse skeletal muscle fragility in vivo by eccentric running exercise. *Muscle Nerve* 21:567-576
- Webster C**, Silberstein L, Hays AP, Blau HM (1988) Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. *Cell* 52:503-513
- Weller B**, Karpati G, Carpenter S (1990) Dystrophin-deficient *mdx* muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. *J Neurol Sci* 100:9-13
- Wells DJ**, Wells KE, Asante EA, Turner G, Sunada Y, Campbell KP, Walsh FS, Dickson G (1995) Expression of human full-length and minidystrophin in transgenic *mdx* mice: implications for gene therapy of Duchenne muscular dystrophy. *Hum Mol Genet* 4:1245-1250
- Wersinger E**, Bordais A, Schwab Y, Sene A, Benard R, Alunni V, Sahel JA, Rendon A, Roux MJ (2011) Re-Evaluation of Dystrophins Localization in the Mouse Retina. *Invest Ophthalmol Vis Sci* 11:7901-7908
- Whitehead NP**, Yeung EW, Allen DG (2006) Muscle damage in *mdx* (dystrophic) mice: role of calcium and reactive oxygen species. *Clin Exp Pharmacol Physiol* 33:657-662
- Wiesen MH**, Bogdanovich S, Agarkova I, Perriard JC, Khurana TS (2007) Identification and characterization of layer-specific differences in extraocular muscle m-bands. *Invest Ophthalmol Vis Sci* 48:1119-1127
- Willmann R**, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers JM, Nagaraju K (2011) Enhancing translation: Guidelines for standard pre-clinical experiments in *mdx* mice. *Neuromuscul Disord* 1:43-49
- Willmann R**, Possekel S, Dubach-Powell J, Meier T, Ruegg MA (2009) Mammalian animal models for Duchenne muscular dystrophy. *Neuromuscul Disord* 19:241-249
- Wilson J**, Putt W, Jimenez C, Edwards YH (1999) Up71 and up140, two novel transcripts of utrophin that are homologues of short forms of dystrophin. *Hum Mol Genet* 8:1271-1278
- Wilton SD**, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, Kole R (1999) Specific removal of the nonsense mutation from the *mdx* dystrophin mRNA using antisense oligonucleotides. *Neuromuscul Disord* 9:330-338
- Winder SJ**, Gibson TJ, Kendrick-Jones J (1995) Dystrophin and utrophin: the missing links! *FEBS Lett* 369:27-33
- Wooddell CI**, Zhang G, Griffin JB, Hegge JO, Huss T, Wolff JA (2010) Use of Evans blue dye to compare limb muscles in exercised young and old *mdx* mice. *Muscle Nerve* 41:487-499
- Wu B**, Xiao B, Cloer C, Shaban M, Sali A, Lu P, Li J, Nagaraju K, Xiao X, and Lu QL (2011) One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic *mdx* mice. *Mol Ther* 19:576-583

- Wu ZS**, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. *Int J Cancer* 122:2050-2056
- Yilmaz A**, Gdynia HJ, Baccouche H, Mahrholdt H, Meinhardt G, Basso C, Thiene G, Sperfeld AD, Ludolph AC, and Sechtem U (2008) Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. *J Cardiovasc Magn Reson* 10,50
- Yin H**, Moulton HM, Betts C, Merritt T, Seow Y, Ashraf S, Wang Q, Boutilier J, Wood MJ (2010) Functional rescue of dystrophin-deficient *mdx* mice by a chimeric peptide-PMO. *Mol Ther* 18:1822-1829
- Yin H**, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJ (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient *mdx* mice. *Hum Mol Genet* 18:4405-4414
- Yin H**, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJ (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. *Hum Mol Genet* 17:3909-3918
- Yin H**, Saleh AF, Betts C, Camelliti P, Seow Y, Ashraf S, Arzumanov A, Hammond S, Merritt T, Gait MJ, Wood MJ (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in *mdx* mice. *Mol Ther* 19:1295-1303
- Yokota T**, Lu QL, Morgan JE, Davies KE, Fisher R, Takeda S, Partridge TA (2006) Expansion of revertant fibers in dystrophic *mdx* muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. *J Cell Sci* 119:2679-2687
- Yokota T**, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. *Ann Neurol* 65:667-676
- Yue Y**, Liu M, Duan D (2006) C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. *Mol Ther* 14:79-87
- Zhang W**, ten Hove M, Schneider JE, Stuckey DJ, Sebag-Montefiore L, Bia BL, Radda GK, Davies KE, Neubauer S, Clarke K (2008) Abnormal cardiac morphology, function and energy metabolism in the dystrophic *mdx* mouse: an MRI and MRS study. *J Mol Cell Cardiol* 45:754-760
- Zhou L**, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM (2008) Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in *mdx* mice. *J Neurosci* 264:106-111

